

Brookdale Senior Living Inc. (BKD)

NYSE: healthcare: SIC 8050, Services-Nursing & Personal Care Facilities: CIK 0001332349

Brookdale Senior Living Inc.	
BKD; healthcare	
Grade	E weakest fifth of 371 graded peers percentile 89.7; sampling error 2.5 points; lower is stronger
Rank	333 of 371
Profitability	C/D percentile 62.1
Solvency	D percentile 75.4
Growth and financing	D percentile 67.7
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$6.0B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active
Inputs computable	12 of 14
Graded from	filings received through Feb 19, 2026 232 days before the rescans; latest periodic filing 10-Q received Aug 10, 2026
Last close	\$10.88 2026-10-08; market equity \$2.6B
Price used in grade	None


E, the bear
weakest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it

Rescans on file: D/E from Mar 21, 2024, E from Feb 21, 2025, D/E from Oct 2, 2025

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

Unless otherwise specified, references to "Brookdale," "we," "us," "our," or "the Company" in this Annual Report on Form 10-K mean Brookdale Senior Living Inc. together with its consolidated subsidiaries. We are the nation's premier operator of senior living communities, operating and managing 584 communities in 41 states as of December 31, 2025, with the ability to serve approximately 51,000 residents. We offer our residents access to a broad continuum of services across the most attractive sectors of the senior living industry. We operate and manage independent living, assisted living, memory care, and continuing care retirement communities

("CCRCs").


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 62.1						
Gross profitability		14.1%	32.2%	70.6	372	2025-12-31
Return on invested capital		0.3%	9.3%	74.0	74	2025-12-31
Accruals ratio		(7.8%)	(6.6%)	50.4	811	2025-12-31
Gross margin stability, five years		3.1 pts	2.8 pts	53.3	243	2025-12-31
Solvency, sleeve percentile 75.4						
Twelve-month failure probability		0.20%	0.07%	70.0	248	2026-06-30
Altman Z double-prime		(2.36)	(0.31)	47.0	756	2025-12-31
Net debt to EBITDA		10.46x	1.82x	94.6	75	2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		0.98x	2.96x	90.1	839	2025-12-31
Growth and financing, sleeve percentile 67.7						
Revenue growth, three-year compound		4.2%	10.0%	61.8	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		(865.3%)	37.1%	98.1	104	2025-12-31
Asset growth, three years		0.09%	2.1%	51.4	704	2025-12-31
Net share issuance, one year		18.8%	2.5%	59.4	634	2026-02-17

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
328	Bristol Myers Squibb Co. (CELG-RI)	88.2	E	
329	Maravai Lifesciences Holdings, Inc. (MRVI)	88.6	E	late filer
330	Insight Molecular Diagnostics Inc. (IMDX)	88.9	E	fortress
				balance sheet
331	Nuwellis, Inc. (NUWE)	89.2	E	dilution, short runway, fortress balance sheet

332	Aclaris Therapeutics, Inc. (ACRS)	89.5	E	short runway, fortress balance sheet
333	Brookdale Senior Living Inc. (BKD) <	89.7	E	
334	Lifeward Ltd. (LFWD)	90.0	E	dilution, late filer
335	Canopy Growth Corp. (CGC)	90.3	E	dilution, fortress balance sheet
336	Aytu Biopharma, Inc. (AYTU)	90.5	E	fortress balance sheet
337	Q32 Bio Inc. (QTTB)	90.8	E	
338	Editas Medicine, Inc. (EDIT)	91.1	E	fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	39.2%	8.0%	71
Distance from 52-week high	(35.1%)	(31.4%)	44
EBIT to enterprise value	0.2%	(1.5%)	55
Free cash flow yield	0.6%	(1.0%)	58
Book value to price	(0.01)	0.28	10
Sales to price	1.23	0.31	85
Composite equity issuance, five years	26.4%	20.3%	54
Relative strength against the sector, log excess return	0.12	(0.14)	71

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$370.4M
Operating cash flow, four quarters	\$223.9M
Months of runway	not finite
Days since last periodic filing	60 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	\$55.4M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$837.5M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
2	assets	us-gaap:Assets	\$6.0B	2025-12-31	2026-02-19	10-K	0001332349-26-000032
3	operating income	us-gaap:OperatingIncomeLoss	\$13.5M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItems	\$25.4M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$2.0M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
6	total debt	us-gaap:LongTermDebt	\$4.3B	2025-12-31	2026-02-19	10-K	0001332349-26-000032
7	book equity	us-gaap:StockholdersEquity	-\$44.8M	2025-12-31	2026-02-19	10-K	0001332349-26-000032

8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$279.1M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
9	total debt	us-gaap:LongTermDebt	\$4.1B	2024-12-31	2026-02-19	10-K	0001332349-26-000032
10	book equity	us-gaap:StockholdersEquity	\$212.5M	2024-12-31	2026-02-19	10-K	0001332349-26-000032
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$308.9M	2024-12-31	2026-02-19	10-K	0001332349-26-000032
12	net income	us-gaap:NetIncomeLoss	-\$262.7M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$218.0M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
14	assets	us-gaap:Assets	\$6.3B	2024-12-31	2026-02-19	10-K	0001332349-26-000032
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.2B	2025-12-31	2026-02-19	10-K	0001332349-26-000032
16	gross profit	us-gaap:GrossProfit	\$799.3M	2024-12-31	2026-02-19	10-K	0001332349-26-000032
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.1B	2024-12-31	2026-02-19	10-K	0001332349-26-000032
18	gross profit	us-gaap:GrossProfit	\$746.7M	2023-12-31	2026-02-19	10-K	0001332349-26-000032
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.0B	2023-12-31	2026-02-19	10-K	0001332349-26-000032
20	gross profit	us-gaap:GrossProfit	\$594.4M	2022-12-31	2025-02-19	10-K	0001332349-25-000037
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.8B	2022-12-31	2025-02-19	10-K	0001332349-25-000037
22	gross profit	us-gaap:GrossProfit	\$501.0M	2021-12-31	2024-02-21	10-K	0001332349-24-000041
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$2.8B	2021-12-31	2024-02-21	10-K	0001332349-24-000041
24	current assets	us-gaap:AssetsCurrent	\$553.9M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
25	current liabilities	us-gaap:LiabilitiesCurrent	\$567.9M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$4.3B	2025-12-31	2026-02-19	10-K	0001332349-26-000032
27	liabilities	us-gaap:Liabilities	\$6.0B	2025-12-31	2026-02-19	10-K	0001332349-26-000032
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$370.3M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
29	operating income	us-gaap:OperatingIncomeLoss	\$18.4M	2023-12-31	2026-02-19	10-K	0001332349-26-000032
30	interest expense	us-gaap:InterestExpense	\$238.3M	2023-12-31	2024-02-21	10-K	0001332349-24-000041
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$201.5M	2025-12-31	2026-02-19	10-K	0001332349-26-000032
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$166.2M	2024-12-31	2026-02-19	10-K	0001332349-26-000032
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$201.2M	2024-12-31	2026-02-19	10-K	0001332349-26-000032
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$162.9M	2023-12-31	2026-02-19	10-K	0001332349-26-000032
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$233.2M	2023-12-31	2026-02-19	10-K	0001332349-26-000032
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$3.3M	2022-12-31	2025-02-19	10-K	0001332349-25-000037
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$196.9M	2022-12-31	2025-02-19	10-K	0001332349-25-000037
38	current assets	us-gaap:AssetsCurrent	\$512.9M	2024-12-31	2026-02-19	10-K	0001332349-26-000032
39	current liabilities	us-gaap:LiabilitiesCurrent	\$579.8M	2024-12-31	2026-02-19	10-K	0001332349-26-000032
40	assets	us-gaap:Assets	\$5.6B	2023-12-31	2025-02-19	10-K	0001332349-25-000037
41	assets	us-gaap:Assets	\$5.9B	2022-12-31	2024-02-21	10-K	0001332349-24-000041
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	237,792,413	2026-02-17	2026-02-19	10-K	0001332349-26-000032
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	200,189,063	2025-02-17	2025-04-29	10-K/A	0001193125-25-103994